A Three MiRNAs Panel in Paraffin Tissue Serves As Tool for Predicting Prognosis of Renal Cell Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 May 9

PMID 38720802

Authors

Wenkang Chen

Wuping Wang

Zhengping Zhao

Zhenyu Wen

Yingqi Li

Zhenjian Ge

Yongqing Lai

Liangchao Ni

Affiliations

Soon will be listed here.

Abstract

Background: Renal cell carcinoma (RCC) stands as the most prevalent form of urogenital cancer. However, there is currently no universally accepted method for predicting the prognosis of RCC. MiRNA holds great potential as a prognostic biomarker for RCC.

Methods: A total of 100 cases with complete paraffin specimens and over 5-year follow-up data meeting the requirements were collected. Utilizing the clinical information and follow-up data of the specimens, an information model was developed. The expression levels of eight microRNAs were identified using RT-qPCR. Finally, determine and analyze the clinical application value of these microRNAs as prognostic markers for RCC.

Results: Significant differences were observed in the expression of two types of miRNAs (miR-378a-5p, miR-23a-5p) in RCC tissue, and three types of miRNAs (miR-378a-5p, miR-642a-5p, miR-23a-5p) were found to be linked to the prognosis of RCC. Establish biomarker combinations of miR-378a-5p, miR-642a-5p, and miR-23a-5p to evaluate RCC prognosis.

Conclusion: The combination of three microRNA groups (miR-378a-5p, miR-642a-5p, and miR-23a-5p) identified in paraffin section specimens of RCC in this study holds significant potential as biomarkers for assessing RCC prognosis.

Citing Articles

The key role of miR‑378 in kidney diseases (Review).

Liu Y, Shi S, Cheng T, Wang H, Wang H, Hu Y Mol Med Rep. 2025; 31(4).

PMID: 39981929 PMC: 11868772. DOI: 10.3892/mmr.2025.13466.

References

Flanigan R, Campbell S, Clark J, Picken M . Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003; 4(5):385-90. DOI: 10.1007/s11864-003-0039-2. View

Shi Y, Liu Z, Lin Q, Luo Q, Cen Y, Li J . MiRNAs and Cancer: Key Link in Diagnosis and Therapy. Genes (Basel). 2021; 12(8). PMC: 8395027. DOI: 10.3390/genes12081289. View

Suarez C, Campayo M, Bastus R, Castillo S, Etxanitz O, Guix M . Prognostic and Predictive Factors for Renal Cell Carcinoma. Target Oncol. 2018; 13(3):309-331. DOI: 10.1007/s11523-018-0557-2. View

Li K, Zhang J, Zhang M, Wu Y, Lu X, Zhu Y . miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1. World J Surg Oncol. 2021; 19(1):54. PMC: 7896405. DOI: 10.1186/s12957-021-02166-w. View

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022; 82(4):399-410. DOI: 10.1016/j.eururo.2022.03.006. View

Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016; 70(1):93-105. DOI: 10.1016/j.eururo.2016.02.029. View

Hussen B, Hidayat H, Salihi A, Sabir D, Taheri M, Ghafouri-Fard S . MicroRNA: A signature for cancer progression. Biomed Pharmacother. 2021; 138:111528. DOI: 10.1016/j.biopha.2021.111528. View

Zou H, Yang L . miR-378a-5p improved the prognosis and suppressed the progression of hepatocellular carcinoma by targeting the VEGF pathway. Transl Cancer Res. 2022; 9(3):1558-1566. PMC: 8798882. DOI: 10.21037/tcr.2020.01.46. View

Klatte T, Rossi S, Stewart G . Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018; 36(12):1943-1952. DOI: 10.1007/s00345-018-2309-4. View

10.

Lu B, Sheng Y, Zhang J, Zheng Z, Ji L . The altered microRNA profile in andrographolide-induced inhibition of hepatoma tumor growth. Gene. 2016; 588(2):124-33. DOI: 10.1016/j.gene.2016.05.012. View

11.

Rini B, Campbell S, Escudier B . Renal cell carcinoma. Lancet. 2009; 373(9669):1119-32. DOI: 10.1016/S0140-6736(09)60229-4. View

12.

Ferrero A, Takahashi N, Vrtiska T, Krambeck A, Lieske J, McCollough C . Understanding, justifying, and optimizing radiation exposure for CT imaging in nephrourology. Nat Rev Urol. 2019; 16(4):231-244. PMC: 6447446. DOI: 10.1038/s41585-019-0148-8. View

13.

Le Saux O, Freyer G, Negrier S . First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review. Clin Drug Investig. 2016; 36(5):389-99. DOI: 10.1007/s40261-016-0384-0. View

14.

Gray R, Harris G . Renal Cell Carcinoma: Diagnosis and Management. Am Fam Physician. 2019; 99(3):179-184. View

15.

Hill M, Tran N . miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021; 14(4). PMC: 8077553. DOI: 10.1242/dmm.047662. View

16.

Mejean A, Oudard S, Thiounn N . Prognostic factors of renal cell carcinoma. J Urol. 2003; 169(3):821-7. DOI: 10.1097/01.ju.0000051378.14270.2a. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Lane B, Kattan M . Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008; 35(4):613-25. DOI: 10.1016/j.ucl.2008.07.003. View

19.

Lu T, Rothenberg M . MicroRNA. J Allergy Clin Immunol. 2017; 141(4):1202-1207. PMC: 5889965. DOI: 10.1016/j.jaci.2017.08.034. View

20.

Hashiguchi Y, Nishida N, Mimori K, Sudo T, Tanaka F, Shibata K . Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol. 2012; 40(5):1477-82. DOI: 10.3892/ijo.2012.1363. View